Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma

Currently, five biologic treatment options are available for use in patients with uncontrolled persistent asthma: three interleukin (IL)-5 antagonists, which either bind to the anti-IL-5 ligand (mepolizumab, reslizumab) or to the IL-5 receptor (benralizumab);one anti-immunoglobulin E (anti-IgE) therapy (omalizumab); and one anti-IL-4/IL-13 therapy (dupilumab). To date, no comparative data from head-to-head clinical trials are available for these biologics.

Source: Respiratory Medicine - April 28, 2020 Category: Respiratory Medicine Authors: Eric D. Bateman, Asif H. Khan, Yingxin Xu, Patricia Guyot, Jingdong Chao, Siddhesh Kamat, Paul Rowe, Heather Burnett, Jerome Msihid, David Weinreich, Ian D. Pavord Source Type: research